Results 231 to 240 of about 10,552,439 (323)

Significant underascertainment in Huntington's disease. [PDF]

Brain Commun
Lee S, Weisburd B, Lee J, Correia K, Zeng S, Park SS, Shin JW, Choi DE, Kim KH, Jang JH, Gillis T, Rehm HL, Gusella JF, MacDonald ME, Lee JM.   +14 more
europepmc   +1 more source

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) can be caused by autosomal‐dominant familial Alzheimer's disease (FAD) mutations in amyloid precursor protein (APP) or presenilin‐1 and 2, which form an enzyme substrate complex. KAT5 binds to the APP intracellular domain.
Greg A Cary, Jessica E. Young, Shannon E. Rose, Harald Frankowski, Heather Wilkins, Sai Sruthi Amirtha Ganesh, Julia Draper, Martin Darvas, Mark Bothwell, Suman Jayadev, Aquene N. Reid, Anna Greenwood, Allan I. Levey, Karina Leal, Gregory W. Carter, Jesse C. Wiley   +15 more
wiley   +1 more source

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract The Dame Barbara Windsor Dementia Goals Programme was launched by the UK Government to accelerate the development and delivery of new treatments for dementia. We present the recommendations from the Scientific Advisory Board, to enable timely access to therapies for the wider population, reducing health system burden while improving patient ...
Ruth M. McKernan, James B. Rowe, Sally John, Eric Karran, Helene A. Fachim, Sara Imarisio, Raj Long, Charlotte Teunissen, Sarah P. Slight, Catherine Mummery, John Hardy   +10 more
wiley   +1 more source

Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease. [PDF]

Brain Commun
Franch-Marti C, Puig-Davi A, Rodriguez-Antiguedad J, Perez-Perez J, Olmedo-Saura G, Ruiz-Barrio I, Bojtos L, Perez-Carasol L, Tort-Merino A, Pagonabarraga J, Kulisevsky J, Martinez-Horta S.   +11 more
europepmc   +1 more source

The ‘hidden no more’ mass lobby June 2010 - using oral histories and cultural representations to explore the concealment of Huntington’s disease [PDF]

Harrison, Jacqueline Sophie
core  

Nuclear dysfunction in aging and neurodegeneration

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract Neurodegenerative diseases are characterized by a loss of neuronal function and structure, often in a region‐specific manner. Multiple factors contribute to neuronal dysfunction and death, including pathogenic protein buildup, protein mislocalization, and inflammation. Despite extensive research, the common mechanisms driving neurodegeneration
Abbigael Aday, Jack Tiller, Adarsh Melukote, Zachary C. Walton, Anna King, Luke Castillo, Rakez Kayed, Mauro Montalbano   +7 more
wiley   +1 more source

Development and validation of the first needs-based quality of life measure for individuals with manifest Huntington's disease. [PDF]

J Neurol
Spray I, Grzeda MT, Thorpe J, Johnstone E, Hannemann W, Squitieri F, Giancaterino G, Mina PE, D'Alessio B, Arnesen A, Klempíř J, Ulmanová O, van Lonkhuizen P, Heemskerk AW, Hoblyn J, O'Malley E, Moldovan R, Landwehrmeyer GB, McKenna SP, Mühlbäck A, HEALTHE-RND consortium.   +20 more
europepmc   +1 more source

Advances in the Core Role and Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease

Brain and Behavior, Volume 16, Issue 7, July 2026.
In Alzheimer's disease, Aβ and Tau trigger mitochondrial dysfunction, driving a pathological cascade that results in cognitive decline. Gut microbiota dysbiosis exacerbates this via the gut–brain axis, making mitochondria a key therapeutic target. ABSTRACT Introduction Alzheimer's disease (AD) is a complex neurodegenerative disorder whose pathogenesis ...
Tianyi Gu, Hangyan Guo, Zixin Guo, Shengyu Hua   +3 more
wiley   +1 more source